GlassScriptPhysician profile
Atoosa Molanazadeh
NPI 1619404431
$4,059.69
in general payments reported to CMS, 2019-2025
11 companies · $866 in 2025
The $866 reported for 2025 was more than what 78% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,531 · 2022: $869 · 2023: $274 · 2024: $520 · 2025: $866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,440 · Travel and Lodging: $219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,440.47 |
| Travel and Lodging | $219.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,282.04 | 2021-2025 | Micra, Symplicity G3 |
| Edwards Lifesciences Corporation | $836.93 | 2022-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boston Scientific Corporation | $330.06 | 2022-2023 | Watchman Flx, Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.90 | 2023-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $120.48 | 2023-2024 | Farxiga |
| Philips North America LLC | $88.86 | 2024-2025 | Mcot, (5044) Mcot |
| Irhythm Technologies, INC. | $53.89 | 2024 | Zio Monitor, Zio Xt Patch |
| Esperion Therapeutics, INC. | $44.43 | 2023-2025 | Nexletol |
| Amgen INC. | $31.69 | 2025 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.19 | 2023-2024 | Lifevest |
| Sanofi-Aventis U.S. LLC | $18.22 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atoosa Molanazadeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.